|1.||Widdop, Robert E: 4 articles (01/2014 - 11/2004)|
|2.||Black, M Jane: 3 articles (01/2012 - 11/2004)|
|3.||Zhang, Yun: 2 articles (05/2015 - 01/2015)|
|4.||Zhang, Cheng: 2 articles (05/2015 - 01/2015)|
|5.||Vinh, Antony: 2 articles (01/2014 - 04/2009)|
|6.||McCarthy, Claudia A: 2 articles (01/2014 - 04/2009)|
|7.||Callaway, Jennifer K: 2 articles (01/2014 - 04/2009)|
|8.||Gao, Lie: 2 articles (10/2013 - 10/2008)|
|9.||Jones, Emma S: 2 articles (01/2012 - 11/2004)|
|10.||Barreto-Chaves, M L M: 2 articles (05/2010 - 04/2007)|
12/02/1997 - "Treatment with an AT1-R antagonist, TCV116, for 20 weeks inhibited progression of interstitial fibrosis by 28%, whereas with 44-week PD123319 treatment but not 20-week treatment, the extent of the fibrous region was increased significantly, by 29%. "
08/01/2014 - "At low concentrations PD123319 attenuates cardiopulmonary injury by reducing pulmonary inflammation and fibrosis and preventing PAH-induced RVH but does not affect alveolar and vascular development in newborn rats with experimental BPD. "
11/01/2004 - "However, PD123319 did reverse AT(1)R-mediated regression of cardiovascular hypertrophy and fibrosis, highlighting the important role of the AT(2)R on cardiovascular structure in the ageing heart and vasculature."
12/01/2008 - "Discussion of the results of a preclinical study assessing the antifibrotic efficacy of olmesartan and PD123319 in an experimental lung fibrosis. "
01/01/2012 - "Perivascular fibrosis was significantly reduced by candesartan cilexetil in aged animals only, and this effect was reversed by concomitant PD123319 administration. "
12/01/1994 - "PD-123319 is an AT2 agonist and improved survival in this animal model of stroke. "
01/01/2014 - "Spontaneously hypertensive rats (SHR) were pre-treated for 5 days prior to stroke with C21 alone or in combination with the AT2R antagonist PD123319. "
09/01/2005 - "No significant changes in blood pressure (p=0.92), cardiac index (p=0.52), stroke index (p=0.61), systemic vascular resistance index (p=0.32) or stiffness index (p=0.57) was demonstrated following PD 123319 infusion, compared with placebo. "
04/01/2009 - "Spontaneously hypertensive rats were treated with either CGP42112 (0.1 to 10 ng/kg/min intracerebroventricularly) alone or in combination with the AT(2)R antagonist PD123319 (36 ng/kg/min intracerebroventricularly) beginning 5 days before stroke induction. "
03/01/2002 - "Ang II infusion, however, induced a significant reduction in glomerular monocyte infiltration, cell proliferation and matrix expansion in nephritic rats compared to rats with nephritis without Ang II. The antiproliferative effect of Ang II was inhibited by the Ang II type 1 (AT1) receptor blocker irbesartan, but not by the AT2 receptor blocker PD 123319, indicating that this effect was likely transduced by AT1 receptors. "
02/01/2004 - "We investigated the glomerular expression of TGF-beta1 type I (TbetaRI) and II (TbetaRII) TGF-beta receptors and RAS components in rats with antithymocyte serum (ATS) nephritis on normal (NSI)-, low (LSI)-, and high-salt intake (HSI) and on HSI rats receiving candesartan cilexetil (CC) and LSI rats receiving PD-123319. "
|4.||Hypoglycemia (Reactive Hypoglycemia)
01/01/1998 - "Thus, combined treatment with losartan + PD 123319 proved more effective in attenuating the reflex increase in plasma epinephrine concentration during hypoglycemia than either of the two AT receptor antagonists given alone. "
04/01/2001 - "To examine the role of brain AT1 and AT2 receptors in the reflex regulation of Epi release, we measured catecholamines, hemodynamics, and renin during insulin-induced hypoglycemia in conscious rats pretreated intracerebroventricularly with losartan, PD-123319, losartan and PD-123319, or vehicle. "
01/01/1998 - "In conscious chronically instrumented rats, we measured plasma concentrations of catecholamines during acute insulin-induced hypoglycemia in groups of rats pretreated with the AT1 receptor antagonist losartan (10 mg/kg i.v.), the AT2 receptor antagonist PD123319 (30 mg/kg i.v.), combined losartan + PD123319, the converting enzyme inhibitor enalapril (1 mg/kg i.v.), or vehicle. "
|5.||Acute Kidney Injury (Acute Renal Failure)
06/15/2012 - "Eplerenone, an aldosterone receptor blocker, TY-51469, a chymase inhibitor and PD123319, a selective angiotensin II type 2 (AT2) receptor antagonist, but not benazepril, an angiotensin-converting enzyme inhibitor, and candesartan, a selective angiotensin II type 1 (AT1) receptor antagonist improved acute renal failure caused by cisplatin, confirming involvement of IL-18, aldosterone and angiotensin II in cisplatin-induced, chymase-dependent acute renal failure in mice. "
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Interleukin-18 (Interleukin 18)
|1.||Surgical Instruments (Clip)
|4.||Drug Therapy (Chemotherapy)